Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BCT194 · 2 trials · 1 indication
Interstitial fluid will be collected and concentrations of BCT194 determined determined on Day 1 and Day 8 at several timepoints
Interstitial fluid will be collected and concentrations of BCT194 determined on Day 1 and Day 8 at several timepoints
| Arm | Type | Description |
|---|---|---|
| BCT194 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BCT194 | DRUG | Topically applied BCT194 cream (0.5%) |
Inclusion criteria: * Male patients and post menopausal or surgically sterile female patients aged 18 - 75 years. * Diagnosis of stable plaque psoriasis (with or without arthritis); diagnosed or history of psoriasis for at least 6 months prior to screening * Psoriatic plaques accessible for micrope...
BCT194 is an investigational small molecule being developed for the treatment of psoriasis. It is currently in Phase 1 clinical development, with studies conducted in patients with psoriasis to evaluate its safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics.
BCT194 is being developed by Novartis AG, a multinational pharmaceutical company listed on the stock exchange under the ticker NVS. The company is conducting clinical trials to evaluate the drug's potential as a treatment for psoriasis.
BCT194 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. Two Phase 1 trials have been completed, involving a total of 47 participants with psoriasis.
BCT194 has been studied in two completed Phase 1 clinical trials. The first trial, NCT00417820, enrolled 35 participants and assessed safety, tolerability, and efficacy in healthy volunteers and psoriasis patients. The second trial, NCT01539915, enrolled 12 psoriatic patients to evaluate pharmacokinetics and pharmacodynamics.
The specific molecular target of BCT194 has not been disclosed in the available clinical trial information. The drug is a small molecule being investigated for its effects in psoriasis, but its mechanism of action has not been publicly detailed.